Novavax (NVAX) Reports Q4 EPS of ($11.28), Guides 2022 Revenue of $4-$5B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
February 28, 2022 4:02 PM ESTGAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ --
NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union, Australia, Canada, and Great Britain; authorizations granted by 12 regulatory agencies and emergency use listing from the WHO Additional filings for authorization under review, including in the United States Initiated vaccine shipments globally, with doses administered in the European Union, Australia, Indonesia and South Korea Expanded clinical body of evidence for NVX-CoV2373 across several studies, including: 82.5% overall... More